within Pharmacolibrary.Drugs.ATC.J;

model J01FA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.00022333333333333333,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0125,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.083,
    k12             = 26.3,
    k21             = 26.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01FA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Erythromycin is a macrolide antibiotic used primarily for the treatment of respiratory tract infections, skin infections, and some sexually transmitted infections. It is active against many Gram-positive bacteria and some Gram-negative bacteria. Erythromycin is approved and still used clinically, although its use has declined with the introduction of newer macrolides.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose of erythromycin base.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02167-19&quot;>10.1128/AAC.02167-19</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31871085/&quot;>https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Welling, PG, &amp; Craig, WA (1978). Pharmacokinetics of intravenous erythromycin. <i>Journal of pharmaceutical sciences</i> 67(8) 1057–1059. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600670809&quot;>10.1002/jps.2600670809</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/671237/&quot;>https://pubmed.ncbi.nlm.nih.gov/671237</a></p></li><li><p>Escudero, AI, et al., &amp; Escudero, E (2018). Pharmacokinetics of deflazacort in rabbits after intravenous and oral administration and its interaction with erythromycin. <i>Journal of veterinary pharmacology and therapeutics</i> 41(1) e10–e15. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12442&quot;>10.1111/jvp.12442</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28741668/&quot;>https://pubmed.ncbi.nlm.nih.gov/28741668</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01FA01;
